Abstract
Background: Diabetes mellitus is best described as a condition that is characterized by postprandial hyperglycemia that has two types; diabetes type 1 and type 2. Many patients with type 2 diabetes can be asymptomatic. There are many novel biomarkers for the detection of diabetes type 2, such as FABP1, which is investigated as a marker to detect patients with diabetes type 2. Aim: The aim of the study was to investigate FABP1 in Patients with diabetes type 2 and to find the correlations between FABP1 and fasting insulin in those patients. Methods: Samples were collected from 99 diabetic patients and 85 samples of healthy participants as the control group. All participants were subjected to liver enzymes (ALT and AST) lipid profile (triglycerides, HDL, LDL, and cholesterol), T-billirbun, Albumin, Alp, AFP, BMI, S-creatinine, Hb, Fatty acids, F. Insulin, CA19.9, HbA1c, and Fbs that were done by an autoanalyzer. The serum level of fatty acid-binding protein 1 was measured by SunRed human FABP1 Elisa kits. Results: Data was represented as mean ± standard deviation or median with statistically significant values of ALT, AST, ALP, PT, and INR (at P< 0.05). Findings revealed a significant positive correlation between our marker FABP1 and TG, cholesterol, LDL, Fasting insulin, and CA19.9, Conclusion: FABP1 can be used as a novel marker to detect patients with diabetes type 2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
